Targeting Strategies for Renal Cancer Stem Cell Therapy

Author(s): Pengchao Fang, Liuting Zhou, Lee Y. Lim, Hualin Fu, Zhi-xiang Yuan*, Juchun Lin*.

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 17 , 2020

Become EABM
Become Reviewer


Renal cell carcinoma (RCC) is an intractable genitourinary malignancy that accounts for approximately 4% of adult malignancies. Currently, there is no approved targeted therapy for RCC that has yielded durable remissions, and they remain palliative in intent. Emerging evidence has indicated that renal tumorigenesis and RCC treatment-resistance may originate from renal cancer stem cells (CSCs) with tumor-initiating capacity (CSC hypothesis). A better understanding of the mechanism underlying renal CSCs will help to dissect RCC heterogeneity and drug treatment efficiency, to promote more personalized and targeted therapies. In this review, we summarized the stem cell characteristics of renal CSCs. We outlined the targeting strategies and challenges associated with developing therapies that target renal CSCs angiogenesis, immunosuppression, signaling pathways, surface biomarkers, microRNAs and nanomedicine. In conclusion, CSCs are an important role in renal carcinogenesis and represent a valid target for treatment of RCC patients.

Keywords: Renal cell carcinoma, renal cancer stem cells, signal pathways, biomarkers, targeting strategy, microRNAs.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2020
Page: [1964 - 1978]
Pages: 15
DOI: 10.2174/1381612826666200318153106
Price: $65

Article Metrics

PDF: 11